Form 4 for PRAX Praxis Precision Medicines, Inc.
Accepted 2026-06-26 17:09:23 ET · period of report 2026-06-24 · accession 0001930479-26-000003 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMT | 2026-06-26 17:09 | 2026-06-24 | PRAX | DeSimone Jill | Dir | M - OptEx | $71.20 | +11.6K | 13.9K | +496% | +$826.0K |
| DMT | 2026-06-26 17:09 | 2026-06-24 | PRAX | DeSimone Jill | Dir | S - Sale+OE | $311.32 | -11.6K | 2,337 | -83% | -$3.61M |
| DMT | 2026-06-26 17:09 | 2026-06-24 | PRAX | DeSimone Jill | Dir | M - OptEx | $0.00 | -11.6K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-06-24 | M | A | 8,566 | $44.25 | 10,903 | D | — | — | |
| 2 | Common | Common Stock | 2026-06-24 | M | A | 3,034 | $147.30 | 13,937 | D | — | — | |
| 3 | Common | Common Stock | 2026-06-24 | S | D | 10 | $301.44 | 13,927 | D | — | — | (F1) The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on March 25, 2026. |
| 4 | Common | Common Stock | 2026-06-24 | S | D | 120 | $303.13 | 13,807 | D | — | — | (F1) The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on March 25, 2026. (F2) The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $302.500 to $303.440. The Reporting Person undertakes to provide upon request from the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. |
| 5 | Common | Common Stock | 2026-06-24 | S | D | 320 | $305.31 | 13,487 | D | — | — | (F1) The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on March 25, 2026. (F3) The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $305.000 to $305.830. The Reporting Person undertakes to provide upon request from the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. |
| 6 | Common | Common Stock | 2026-06-24 | S | D | 683 | $306.77 | 12,804 | D | — | — | (F1) The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on March 25, 2026. (F4) The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $306.365 to $307.180. The Reporting Person undertakes to provide upon request from the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. |
| 7 | Common | Common Stock | 2026-06-24 | S | D | 1,240 | $308.24 | 11,564 | D | — | — | (F1) The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on March 25, 2026. (F5) The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $307.900 to $308.870. The Reporting Person undertakes to provide upon request from the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. |
| 8 | Common | Common Stock | 2026-06-24 | S | D | 999 | $309.38 | 10,565 | D | — | — | (F1) The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on March 25, 2026. (F6) The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $308.900 to $309.790. The Reporting Person undertakes to provide upon request from the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. |
| 9 | Common | Common Stock | 2026-06-24 | S | D | 1,750 | $310.89 | 8,815 | D | — | — | (F1) The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on March 25, 2026. (F7) The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $310.340 to $311.300. The Reporting Person undertakes to provide upon request from the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. |
| 10 | Common | Common Stock | 2026-06-24 | S | D | 2,854 | $311.91 | 5,961 | D | — | — | (F1) The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on March 25, 2026. (F8) The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $311.340 to $312.320. The Reporting Person undertakes to provide upon request from the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. |
| 11 | Common | Common Stock | 2026-06-24 | S | D | 1,004 | $312.83 | 4,957 | D | — | — | (F1) The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on March 25, 2026. (F9) The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $312.370 to $313.280. The Reporting Person undertakes to provide upon request from the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. |
| 12 | Common | Common Stock | 2026-06-24 | S | D | 504 | $313.66 | 4,453 | D | — | — | (F1) The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on March 25, 2026. (F10) The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $313.400 to $314.000. The Reporting Person undertakes to provide upon request from the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. |
| 13 | Common | Common Stock | 2026-06-24 | S | D | 1,279 | $314.90 | 3,174 | D | — | — | (F1) The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on March 25, 2026. (F11) The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $314.400 to $315.380. The Reporting Person undertakes to provide upon request from the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. |
| 14 | Common | Common Stock | 2026-06-24 | S | D | 837 | $315.70 | 2,337 | D | — | — | (F1) The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on March 25, 2026. (F12) The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $315.590 to $316.010. The Reporting Person undertakes to provide upon request from the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. |
| 15 | Derivative | Stock Option (Right to Buy) | 2026-06-24 | M | D | 8,566 | $0.00 | 0 | D | $44.25 · — to 2034-06-05 | 8,566 Common Stock | (F13) This option was fully vested as of June 5, 2025. |
| 16 | Derivative | Stock Option (Right to Buy) | 2026-06-24 | M | D | 3,034 | $0.00 | 0 | D | $147.30 · — to 2032-05-23 | 3,034 Common Stock | (F14) This option was fully vested as of May 23, 2025. |